lifitegrast Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
integrin antagonists 5174 1025967-78-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • lifitegrast
  • SAR 1118-023
  • SAR 1118
  • SAR-1118
  • xiidra
a lymphocyte function-associated antigen-1 ( LFA-1) antagonist, blocks the interaction of LFA-1 with its cognate ligand intercellular adhesion molecule-1 (ICAM-1), LFA-1/ICAM-1 interaction can contribute to the formation of an immunological synapse resulting in T-cell activation and migration to target tissues
  • Molecular weight: 615.48
  • Formula: C29H24Cl2N2O7S
  • CLOGP: 2.28
  • LIPINSKI: 1
  • HAC: 9
  • HDO: 2
  • TPSA: 133.99
  • ALOGS: -5.03
  • ROTB: 7

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
July 11, 2016 FDA SHIRE DEV LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Instillation site pain 2914.69 48.53 400 4982 508 46680172
Instillation site reaction 2288.01 48.53 300 5082 180 46680500
Eye irritation 1074.82 48.53 270 5112 16344 46664336
Vision blurred 1071.92 48.53 384 4998 79324 46601356
Dysgeusia 621.15 48.53 216 5166 40275 46640405
Instillation site irritation 599.62 48.53 78 5304 37 46680643
Instillation site pruritus 558.08 48.53 71 5311 17 46680663
Instillation site erythema 517.60 48.53 67 5315 28 46680652
Instillation site lacrimation 427.63 48.53 54 5328 9 46680671
Eye pain 318.64 48.53 120 5262 27820 46652860
Dry eye 263.58 48.53 107 5275 30215 46650465
Instillation site discharge 258.40 48.53 33 5349 9 46680671
Lacrimation increased 228.48 48.53 81 5301 15780 46664900
Ocular hyperaemia 225.77 48.53 85 5297 19625 46661055
Instillation site swelling 217.91 48.53 27 5355 0 46680680
Eye discharge 188.22 48.53 53 5329 4875 46675805
Product container issue 181.43 48.53 42 5340 1757 46678923
Instillation site discomfort 169.47 48.53 21 5361 0 46680680
Product quality issue 159.17 48.53 79 5303 35569 46645111
Eye pruritus 131.39 48.53 50 5332 11848 46668832
Visual impairment 120.30 48.53 82 5300 66607 46614073
Product use complaint 99.70 48.53 26 5356 1786 46678894
Instillation site dryness 93.38 48.53 12 5370 4 46680676
Ocular discomfort 90.76 48.53 27 5355 3008 46677672
Instillation site inflammation 88.76 48.53 11 5371 0 46680680
Eyelid margin crusting 85.35 48.53 19 5363 664 46680016
Eye disorder 83.24 48.53 41 5341 18100 46662580
Inappropriate schedule of product administration 83.22 48.53 65 5317 64948 46615732
Instillation site foreign body sensation 78.07 48.53 10 5372 3 46680677
Instillation site burn 72.62 48.53 9 5373 0 46680680
Product packaging quantity issue 70.65 48.53 18 5364 1126 46679554
Taste disorder 65.93 48.53 25 5357 5853 46674827
Eye swelling 62.44 48.53 35 5347 20068 46660612
Foreign body sensation in eyes 61.84 48.53 18 5364 1858 46678822
Instillation site hypersensitivity 56.48 48.53 7 5375 0 46680680

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Instillation site reaction 613.65 120.68 67 840 22 29951549
Instillation site pain 505.70 120.68 58 849 61 29951510
Vision blurred 444.99 120.68 122 785 41694 29909877
Eye irritation 359.44 120.68 71 836 5625 29945946
Instillation site lacrimation 131.78 120.68 14 893 0 29951571

Pharmacologic Action:

SourceCodeDescription
ATC S01XA25 SENSORY ORGANS
OPHTHALMOLOGICALS
OTHER OPHTHALMOLOGICALS
Other ophthalmologicals
MeSH PA D009883 Ophthalmic Solutions
MeSH PA D019999 Pharmaceutical Solutions
FDA MoA N0000192700 Lymphocyte Function-Associated Antigen-1 Antagonists
FDA EPC N0000192701 Lymphocyte Function-Associated Antigen-1 Antagonist
CHEBI has role CHEBI:35472 anti-inflammatory drugs
CHEBI has role CHEBI:133024 lfa-1 antagonist

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Tear film insufficiency indication 46152009

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.42 acidic
pKa2 12.3 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
5% XIIDRA NOVARTIS N208073 July 11, 2016 RX SOLUTION/DROPS OPHTHALMIC July 11, 2021 NEW CHEMICAL ENTITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Integrin alpha-L/beta-2 Adhesion ANTAGONIST IC50 8.05 SCIENTIFIC LITERATURE DRUG LABEL
Intercellular adhesion molecule 1 Unclassified IC50 8.53 CHEMBL

External reference:

IDSource
D10374 KEGG_DRUG
4035938 VANDF
C3713860 UMLSCUI
CHEBI:133023 CHEBI
CHEMBL2048028 ChEMBL_ID
CHEMBL2048409 ChEMBL_ID
DB11611 DRUGBANK_ID
C575157 MESH_SUPPLEMENTAL_RECORD_UI
7533 IUPHAR_LIGAND_ID
9584 INN_ID
038E5L962W UNII
11965427 PUBCHEM_CID
1801820 RXNORM
243704 MMSL
31873 MMSL
016935 NDDF
720489009 SNOMEDCT_US
763569006 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Xiidra HUMAN PRESCRIPTION DRUG LABEL 1 0078-0911 SOLUTION/ DROPS 50 mg OPHTHALMIC NDA 24 sections
Xiidra HUMAN PRESCRIPTION DRUG LABEL 1 54092-606 SOLUTION/ DROPS 50 mg OPHTHALMIC NDA 23 sections